The face change people have given a brand-name nickname is facial volume loss during rapid weight loss. The face carries fat pads like the rest of the body, they are thin, and they sit on the most-looked-at surface a person owns — so weight coming off shows up there early and unmistakably. The best available measurement found it tracks how much weight was lost rather than which medicine helped produce it. This article sets out what that study measured, why the face goes first, and the one thing that genuinely changes the picture.
Availability in Singapore. This medicine is registered with Singapore's Health Sciences Authority for type 2 diabetes only. It has no registered weight-management indication here, so prescribing it for weight is off-label: a decision only a doctor who has assessed you can make, and one they may decide against. Which medicine suits a particular person, if any does, is decided by the doctor who assesses them — we do not promote a named product.
Worth noting on the way past, since that nickname carries a brand name: the product it is named after is the semaglutide injection registered in Singapore as a type 2 diabetes medicine (HSA register, NDF). The semaglutide injection licensed here for weight management is a separate registration, and what its label says is set out on its own page.
What was actually measured
Until 2025 this was a phenomenon described by surgeons and photographed by newspapers, with no number attached to it.
A retrospective study then queried hospital records for patients who had both a GLP-1 prescription and head or neck imaging before and after it, and measured the change. In 20 patients, median total midfacial volume decreased by 9.0%. Superficial volume fell by 11.0% and deep volume by 7.0%. Linear regression indicated a loss of roughly 7% of midfacial volume for every 10 kg of body weight lost (Sharma 2025).
Twenty patients, retrospectively, at one centre. That is the best evidence that exists on this question, and it is small evidence. Everything below rests on it, and it should be read as a first measurement rather than a settled figure.
Why it is the weight loss rather than the drug
The same study answers this, and the answer is in which volumes moved together with what.
Superficial fat-pad volume loss correlated with how much weight the person had lost. Deep volume loss did not (Sharma 2025). In other words, the part of the face that changed most was the part that behaves like body fat, and it changed in proportion to how much body fat came off.
That fits what has been recognised for decades in people losing weight rapidly after surgery, during illness, or on a severe diet — long before this drug class existed. What the class changed is how many people are doing it, and how quickly.
Why the face shows it first
The facial fat pads are thin, mobile, and doing quiet structural work.
They sit between skin and bone in a layer measured in millimetres, so a proportional loss that would be invisible on a thigh is a visible change on a cheek. And the fullness they provide is a large part of what people read as looking well or looking young — which is why the same person can lose 15 kg, feel much better, and be told they look tired.
The part that is not fat
Skin does not shrink at the same speed as the tissue underneath it.
That is the second half of what people are seeing, and it is worth being honest about how well it is understood: this is a general observation about skin after weight loss rather than something the study above measured. No figure is put on it here, because there is not a good one to put.
What actually changes the picture
Two things, and neither is cosmetic.
How fast the weight comes off. In STEP 1, the average participant lost 15.3 kg over 68 weeks (Wilding 2021). Individual results vary and are not guaranteed. The same total lost over half the time is the same arithmetic and a different experience for the tissue involved. We cover the evidence on rate in how fast should you lose weight.
How much of the loss is fat rather than lean tissue. A 2026 network meta-analysis of 262 trials found the most effective medicine in the class reduced fat mass the most, by 25.7%, and reduced lean mass the most as well, by 8.3% (Nong 2026). Those are pooled trial averages, and individual results vary. Protein intake, resistance training and the rate of loss are what shift that ratio — the subject of how much muscle you lose on GLP-1 medication.
Neither of those buys a particular facial outcome. Nobody can promise one, and a claim that a programme prevents facial volume loss is a claim nobody has the evidence to make.
The part nobody says
Some of this is simply the face of a smaller person.
Weight loss removes a volume that was, among other things, doing some of the work of looking young. Getting it back would mean carrying the fat again. That is a trade rather than a complication, and it is more respectful to name it than to imply it can be engineered away.
Some of it is also a face that was going to age anyway, becoming visible on a shorter timescale than it otherwise would have.
Where it fits
It is not on the side-effect list, and filing it there misplaces the cause. The medicine did not act on the face; the weight loss did. The whole list of things that are side effects is in GLP-1 side effects.
The closest relative is hair shedding, which has the same underlying driver — rapid weight loss — in a different tissue, and which we cover in hair shedding on GLP-1.
If weight is coming off faster than planned, that is worth raising with the doctor managing your treatment. It is a question about the rate of loss and what is being lost, rather than a cosmetic one.
Common questions
What are the face changes people describe on GLP-1 medication?
Facial volume loss during rapid weight loss. The face has fat pads like the rest of the body, they are thin, and they are the most visible tissue a person owns — so weight coming off shows there early. It tracks the amount of weight lost rather than the medicine that helped produce it.
How much facial volume is actually lost?
One 2025 study measured it on imaging in 20 patients before and after GLP-1 prescriptions and found a median 9.0% decrease in total midfacial volume, with regression indicating roughly 7% lost for every 10 kg of body weight (Sharma 2025). That is 20 people in a retrospective single-centre cohort — the best measurement available, and a small one.
Does the drug cause it, or the weight loss?
The evidence points at the weight loss. In the same study, superficial fat-pad volume loss correlated with how much weight a person had lost, while deep volume loss did not (Sharma 2025). Rapid weight loss by any route — surgery, illness, a severe diet — has been recognised in the face long before this drug class existed.
Can it be prevented?
Not prevented. What can change is how much of the loss is fat rather than lean tissue, and how fast it happens — protein intake, resistance training and a sensible rate of loss all bear on that. Nobody can promise a particular facial outcome, and anyone doing so is guessing.
Is this a side effect of the medicine?
It is not listed as one, and describing it that way misplaces the cause. It is a visible consequence of losing weight quickly. That distinction matters, because the things that influence it are the things that shape the weight loss itself rather than anything about the injection.